Denali Therapeutics (DNLI) Income towards Parent Company (2017 - 2024)
Historic Income towards Parent Company for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$114.7 million.
- Denali Therapeutics' Income towards Parent Company rose 400.76% to -$114.7 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$114.7 million, marking a year-over-year increase of 7317.27%. This contributed to the annual value of -$422.8 million for FY2024, which is 19111.79% down from last year.
- Latest data reveals that Denali Therapeutics reported Income towards Parent Company of -$114.7 million as of Q4 2024, which was up 400.76% from -$107.2 million recorded in Q3 2024.
- Denali Therapeutics' Income towards Parent Company's 5-year high stood at $244.9 million during Q4 2020, with a 5-year trough of -$119.5 million in Q4 2023.
- Its 5-year average for Income towards Parent Company is -$55.7 million, with a median of -$79.9 million in 2021.
- In the last 5 years, Denali Therapeutics' Income towards Parent Company soared by 55328.09% in 2020 and then tumbled by 15399.96% in 2024.
- Over the past 5 years, Denali Therapeutics' Income towards Parent Company (Quarter) stood at $244.9 million in 2020, then crashed by 130.73% to -$75.3 million in 2021, then crashed by 31.11% to -$98.7 million in 2022, then fell by 21.07% to -$119.5 million in 2023, then increased by 4.01% to -$114.7 million in 2024.
- Its Income towards Parent Company stands at -$114.7 million for Q4 2024, versus -$107.2 million for Q3 2024 and -$99.0 million for Q2 2024.